Inhibition of AKT abrogates chemotherapy- induced NF-κB survival mechanisms: Implications for therapy in pancreatic cancer

Bridget N. Fahy, Michael G. Schlieman, Subbulakshmi Virudachalam, Richard J Bold

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background When activated, the nuclear factor (NF)-κB pathway is a potent cellular signal that inhibits apoptotic cell death. Pancreatic cancer is resistant to the apoptotic effect of chemotherapy, though it is unclear whether this is an inherent feature or a survival signal engaged in response to chemotherapy. We investigated whether pancreatic cancer cells activate the NF-κB pathway in response to chemotherapy and whether inhibition of this response altered the apoptotic efficacy of chemotherapy. Study design We determined NF-κB activity after chemotherapy treatment of the MIA-PaCa-2 human pancreatic cancer cell line using both physical (electrophoretic mobility shift assay) and functional (luciferase) techniques. The effect of chemotherapy on transcription of the antiapoptotic gene BCL-2, a target of NF-κB, was determined. We examined the effect of inhibition of Akt, an upstream activator of NF-κB, on the molecular (NF-κB function and BCL-2 transcription) and cellular (apoptosis) effect of chemotherapy. Results Both the chemotherapeutic agents gemcitabine and paclitaxel activated NF-κB and stimulated BCL-2 gene promoter activity. The stimulation of BCL-2 promoter function was directly regulated by NF-κB. These cellular responses were blocked by inhibition of Akt. The apoptotic effect of gemcitabine and paclitaxel also was enhanced after Akt inhibition. Conclusions Part of the apoptotic resistance of pancreatic cancer may be mediated by activation of the NF-κB survival pathway in response to chemotherapy. Inhibition of this response may be an important adjunct to increase the efficacy of chemotherapy.

Original languageEnglish (US)
Pages (from-to)591-599
Number of pages9
JournalJournal of the American College of Surgeons
Volume198
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Pancreatic Neoplasms
Drug Therapy
Survival
gemcitabine
Therapeutics
Paclitaxel
Electrophoretic Mobility Shift Assay
Luciferases
Genes
Cell Death
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Surgery

Cite this

Inhibition of AKT abrogates chemotherapy- induced NF-κB survival mechanisms : Implications for therapy in pancreatic cancer. / Fahy, Bridget N.; Schlieman, Michael G.; Virudachalam, Subbulakshmi; Bold, Richard J.

In: Journal of the American College of Surgeons, Vol. 198, No. 4, 04.2004, p. 591-599.

Research output: Contribution to journalArticle

@article{5ca4d94c810d49e696b2a2ef4b3aeddc,
title = "Inhibition of AKT abrogates chemotherapy- induced NF-κB survival mechanisms: Implications for therapy in pancreatic cancer",
abstract = "Background When activated, the nuclear factor (NF)-κB pathway is a potent cellular signal that inhibits apoptotic cell death. Pancreatic cancer is resistant to the apoptotic effect of chemotherapy, though it is unclear whether this is an inherent feature or a survival signal engaged in response to chemotherapy. We investigated whether pancreatic cancer cells activate the NF-κB pathway in response to chemotherapy and whether inhibition of this response altered the apoptotic efficacy of chemotherapy. Study design We determined NF-κB activity after chemotherapy treatment of the MIA-PaCa-2 human pancreatic cancer cell line using both physical (electrophoretic mobility shift assay) and functional (luciferase) techniques. The effect of chemotherapy on transcription of the antiapoptotic gene BCL-2, a target of NF-κB, was determined. We examined the effect of inhibition of Akt, an upstream activator of NF-κB, on the molecular (NF-κB function and BCL-2 transcription) and cellular (apoptosis) effect of chemotherapy. Results Both the chemotherapeutic agents gemcitabine and paclitaxel activated NF-κB and stimulated BCL-2 gene promoter activity. The stimulation of BCL-2 promoter function was directly regulated by NF-κB. These cellular responses were blocked by inhibition of Akt. The apoptotic effect of gemcitabine and paclitaxel also was enhanced after Akt inhibition. Conclusions Part of the apoptotic resistance of pancreatic cancer may be mediated by activation of the NF-κB survival pathway in response to chemotherapy. Inhibition of this response may be an important adjunct to increase the efficacy of chemotherapy.",
author = "Fahy, {Bridget N.} and Schlieman, {Michael G.} and Subbulakshmi Virudachalam and Bold, {Richard J}",
year = "2004",
month = "4",
doi = "10.1016/j.jamcollsurg.2003.12.005",
language = "English (US)",
volume = "198",
pages = "591--599",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibition of AKT abrogates chemotherapy- induced NF-κB survival mechanisms

T2 - Implications for therapy in pancreatic cancer

AU - Fahy, Bridget N.

AU - Schlieman, Michael G.

AU - Virudachalam, Subbulakshmi

AU - Bold, Richard J

PY - 2004/4

Y1 - 2004/4

N2 - Background When activated, the nuclear factor (NF)-κB pathway is a potent cellular signal that inhibits apoptotic cell death. Pancreatic cancer is resistant to the apoptotic effect of chemotherapy, though it is unclear whether this is an inherent feature or a survival signal engaged in response to chemotherapy. We investigated whether pancreatic cancer cells activate the NF-κB pathway in response to chemotherapy and whether inhibition of this response altered the apoptotic efficacy of chemotherapy. Study design We determined NF-κB activity after chemotherapy treatment of the MIA-PaCa-2 human pancreatic cancer cell line using both physical (electrophoretic mobility shift assay) and functional (luciferase) techniques. The effect of chemotherapy on transcription of the antiapoptotic gene BCL-2, a target of NF-κB, was determined. We examined the effect of inhibition of Akt, an upstream activator of NF-κB, on the molecular (NF-κB function and BCL-2 transcription) and cellular (apoptosis) effect of chemotherapy. Results Both the chemotherapeutic agents gemcitabine and paclitaxel activated NF-κB and stimulated BCL-2 gene promoter activity. The stimulation of BCL-2 promoter function was directly regulated by NF-κB. These cellular responses were blocked by inhibition of Akt. The apoptotic effect of gemcitabine and paclitaxel also was enhanced after Akt inhibition. Conclusions Part of the apoptotic resistance of pancreatic cancer may be mediated by activation of the NF-κB survival pathway in response to chemotherapy. Inhibition of this response may be an important adjunct to increase the efficacy of chemotherapy.

AB - Background When activated, the nuclear factor (NF)-κB pathway is a potent cellular signal that inhibits apoptotic cell death. Pancreatic cancer is resistant to the apoptotic effect of chemotherapy, though it is unclear whether this is an inherent feature or a survival signal engaged in response to chemotherapy. We investigated whether pancreatic cancer cells activate the NF-κB pathway in response to chemotherapy and whether inhibition of this response altered the apoptotic efficacy of chemotherapy. Study design We determined NF-κB activity after chemotherapy treatment of the MIA-PaCa-2 human pancreatic cancer cell line using both physical (electrophoretic mobility shift assay) and functional (luciferase) techniques. The effect of chemotherapy on transcription of the antiapoptotic gene BCL-2, a target of NF-κB, was determined. We examined the effect of inhibition of Akt, an upstream activator of NF-κB, on the molecular (NF-κB function and BCL-2 transcription) and cellular (apoptosis) effect of chemotherapy. Results Both the chemotherapeutic agents gemcitabine and paclitaxel activated NF-κB and stimulated BCL-2 gene promoter activity. The stimulation of BCL-2 promoter function was directly regulated by NF-κB. These cellular responses were blocked by inhibition of Akt. The apoptotic effect of gemcitabine and paclitaxel also was enhanced after Akt inhibition. Conclusions Part of the apoptotic resistance of pancreatic cancer may be mediated by activation of the NF-κB survival pathway in response to chemotherapy. Inhibition of this response may be an important adjunct to increase the efficacy of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=1842609941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842609941&partnerID=8YFLogxK

U2 - 10.1016/j.jamcollsurg.2003.12.005

DO - 10.1016/j.jamcollsurg.2003.12.005

M3 - Article

C2 - 15051014

AN - SCOPUS:1842609941

VL - 198

SP - 591

EP - 599

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 4

ER -